Compare ASTE & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTE | XNCR |
|---|---|---|
| Founded | 1972 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | N/A | 2013 |
| Metric | ASTE | XNCR |
|---|---|---|
| Price | $45.59 | $15.55 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $41.00 | $22.78 |
| AVG Volume (30 Days) | 164.8K | ★ 726.1K |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | ★ 1.12% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.08 | N/A |
| Revenue | ★ $1,368,800,000.00 | $150,132,000.00 |
| Revenue This Year | $8.19 | $18.81 |
| Revenue Next Year | $6.23 | N/A |
| P/E Ratio | $22.26 | ★ N/A |
| Revenue Growth | 6.66 | ★ 38.16 |
| 52 Week Low | $29.65 | $6.92 |
| 52 Week High | $50.83 | $25.52 |
| Indicator | ASTE | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 51.58 | 45.69 |
| Support Level | $45.72 | $16.44 |
| Resistance Level | $47.56 | $17.18 |
| Average True Range (ATR) | 1.44 | 0.96 |
| MACD | 0.17 | -0.31 |
| Stochastic Oscillator | 49.62 | 0.63 |
Astec Industries Inc designs and manufactures equipment and components used in road construction and other development activities. Its products are used through the entire process of building roads, from mining and crushing materials to creating the road surface. The company manufactures a line of plants, pavers, vehicles, and machines to mix and transform materials into construction components. It has two operating segments: infrastructure solutions generating maximum revenue and materials solutions. The majority of sales are derived from the United States. Its customers are asphalt producers, highway and heavy equipment contractors, ready mix concrete producers, demolition recycling markets, sand and gravel producers, open mine operators, quarry operators, and others.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.